Evaluation of the performance of the insulin-like growth factor-binding protein-1/alpha-fetoprotein test in diagnosing ruptured fetal membranes in pregnant women.
The objective of this study was to evaluate the efficacy of IGFBP-1/AFP (insulin-like growth factor-binding protein-1/alpha-fetoprotein) immunoassay (Amnioquick Duo+) in diagnosing rupture of membranes (ROM). A prospective, observational study was performed in pregnant women with a history of fluid leakage from the vagina. The IGFBP-1/AFP immunoassay and conventional methods were used to diagnose ROM. The obstetricians were blinded to the results of the IGFBP-1/AFP immunoassay. The diagnosis of ROM was finally confirmed by reviewing the medical records after delivery. One hundred patients were recruited into this study. The mean gestational age was 37.6 weeks (range 25 to 41 weeks). Twenty-six percent were preterm and 74% were at term. IGFBP-1/AFP immunoassay had a sensitivity of 94.1%, specificity of 87.5%, positive predictive value of 97.5%, negative predictive value of 73.7% and accuracy of 93% in diagnosing ROM. IGFBP-1/AFP immunoassay is a rapid immunoassay test for diagnosing ROM with a high sensitivity and specificity. This test can be used as an alternative method for diagnosis of ROM.